This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Psoriasis  • Alert me on articles by topic

Michael Bigby, MD

Arch Dermatol. 2004;140:347-348.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
Heydendael VM, Spuls PI, Opmeer BC, et al
N Engl J Med. 2003;349:658-665

Question: In patients with chronic plaque psoriasis, does treatment with cyclosporine or methotrexate lead to higher rates of clearance, and what toxic effects are associated with each treatment?
Design: Heydendael and colleagues conducted a randomized controlled trial comparing the effectiveness and side effects of methotrexate and cyclosporine and the quality of life they provide.
Setting: Patients were recruited from the Department of Dermatology of the Academic Medical Center in Amsterdam and other dermatologic centers in the Netherlands between October 1998 and June 2000.
Patients: Eligible patients were18 years or older; had moderate to severe chronic plaque psoriasis, defined by a score of at least 8 on the Psoriasis Area and Severity Index (PASI); an insufficient response to topical or UV-B therapy, or both; and . . . [Full Text of this Article]

Comment

Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Mass